NBIX — Neurocrine Biosciences Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $165.92
- YTD price return
- +16.99%
- YTD total return
- +16.99%
- Market cap
- 16.8B
- Enterprise value
- 16.6B
- Shares outstanding
- 101.2M
- 52W low
- $122.14
- 52W high
- $186.12
- From 52W high
- -10.85%
- From 52W low
- +35.84%
- 52W range
- 68%$122–$186
- Beta
- 0.39
Volume
- Rel volume
- 0.81×
- 30D volume
- 1.4M
- 30D $ vol
- 210.9M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$2.3M
- Insider net 3M
- −$3.2M
- Insider net 1Y
- −$70.4M
Form 4 transactions by trade date, as filed; latest on file 2026-11-03.
Fundamentals
- Sales (ttm)
- 3.7B
- Sales/share
- $36.57
- EPS (ttm)
- $6.74
- FCF (ttm)
- 1B
- FCF/share
- $10.27
- Book value/share
- $38.32
- Net margin
- 18.98%
- ROE
- 18.11%
- ROA
- 12.48%
- Current ratio
- 2.04
Growth (CAGR, ttm) · 10Y
- Sales
- +38.01%+27.54%+28.19%+73.49%
- Net income
- +64.19%+54.35%+9.57%n/a
- FCF
- +75.37%+39.28%+25.97%n/a
- Shares
- +1.52%+1.00%+1.30%+1.54%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +61.04%+52.13%+8.09%n/a
- Sales/share
- +35.95%+26.28%+26.54%+70.85%
- FCF/share
- +72.74%+37.91%+24.35%n/a
- Book value/share
- +27.23%+23.43%+21.99%+25.21%
- Price
- +15.59%+15.05%+13.12%+12.44%
- Total return
- +15.59%+15.05%+13.12%+12.44%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 24.6×
- P/OI (ttm)
- 18.9×
- Fwd P/E
- 13.6×
- P/S (ttm)
- 4.5×
- P/B (mrq)
- 4.3×
- P/FCF (ttm)
- 16.2×
- EV/EBITDA (fy)
- 17.1×
- EV/Sales (ttm)
- 4.5×
- FCF yield (ttm)
- 6.19%
- Buyback yield (realized, 1y)
- -1.52%
- Shareholder yield (realized, 1y)
- -1.52%
- Buyback yield (cash, ttm)
- -0.08%
- Shareholder yield (cash, ttm)
- -0.08%
Vs own 10Y history
- P/E
- 14th
- P/OI
- 3rd
- P/S
- 4th
- P/B
- 8th
- P/FCF
- 2nd
Bar = where today’s multiple sits in NBIX’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR +30.6%10Y n/mYoY +38.6%EPS (diluted)
5Y CAGR +2.3%10Y n/mYoY −3.9%Free cash flow
5Y CAGR +28.0%10Y n/mYoY +79.0%TTM: operating cash flow $1.1B, capex −$26.1M
Q3 2026: operating cash flow $395.2M, capex −$11.6M
Shares (diluted)
5Y +4.8%10Y +21.3%YoY +2.6%Net income
5Y CAGR +3.3%10Y n/mYoY −1.4%About Neurocrine Biosciences#
Data provided bySource: Twelve DataNeurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.
San Diego, CA·2,500 employees·Drug Manufacturers - Specialty & Generic·neurocrine.com·As of Oct 28, 2026
Recent filings#
- Nov 2Earnings · Earnings release — EPS $2.78 vs $1.95 est. (+42.6%); revenue $1.12B (+41% y/y) 13.4%
- Jul 30Earnings · Earnings release — EPS $2.36 vs $1.88 est. (+25.5%); revenue $959.0M (+39% y/y) 10.1%
ETFs holding NBIX#
29 of the 193 ETFs ChartRow carries live hold NBIX. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Jul 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 1.3% |
| XBI | SPDR S&P Biotech ETF | 1.0% |
| VBK | Vanguard Small-Cap Growth ETF | 0.5% |
| IJH | iShares Core S&P Mid-Cap ETF | 0.5% |
| MDY | SPDR S&P MidCap 400 ETF Trust | 0.5% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.4% |
| COWZ | Pacer US Cash Cows 100 ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.2% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
